It is believed that Mdm2 suppresses p53 in two ways: transcriptional inhibition by direct binding, and degradation via its E3 ligase activity. To study these functions physiologically, we generated mice bearing a single-residue substitution (C462A) abolishing the E3 function without affecting p53 binding. Unexpectedly, homozygous mutant mice died before E7.5, and deletion of p53 rescued the lethality. Furthermore, reintroducing a switchable p53 by crossing with p53ER TAM mice surprisingly demonstrated that the mutant Mdm2 C462A was rapidly degraded in a manner indistinguishable from that of the wild-type Mdm2. Hence, our data indicate that (1) the Mdm2-p53 physical interaction, without Mdm2-mediated p53 ubiquitination, cannot control p53 activity sufficiently to allow early mouse embryonic development, and (2) Mdm2's E3 function is not required for Mdm2 degradation.
INTRODUCTION
The transcription factor p53 responds to DNA damage and other cellular stressors by inducing cell cycle arrest or apoptosis, thereby playing a critical role in tumor suppression. It is well established that Mdm2 is the major negative regulator of the tumor suppressor p53, yet the mechanism by which Mdm2 suppresses p53 remains inadequately understood. The prevailing view of Mdm2-mediated p53 inhibition is that Mdm2 suppresses p53 via a ''dual'' mechanism-Mdm2 binds to and masks p53's N-terminal transactivation domain, directly interfering with p53's ability to recruit basal transcriptional machinery (Momand et al., 1992; Oliner et al., 1993; Thut et al., 1997) , and/or promotes ubiquitin-mediated degradation of p53 (Haupt et al., 1997; Honda et al., 1997; Kubbutat et al., 1997) .
Studies supporting the masking mechanism include findings that mutations in the transactivation domain of p53 that impair its binding with components of the transcription machinery also disrupt its binding with Mdm2 (Lin et al., 1994) , suggesting that Mdm2 and the basal transcription factors competitively interact with overlapping sequences in p53 (reviewed in Ko and Prives, 1996) . In addition, when recruited to a promoter by fusion SIGNIFICANCE Mdm2 is frequently amplified or overexpressed in human cancers, many of which lack mutations in the p53 tumor suppressor gene; thus, it is believed that Mdm2 overexpression is functionally equivalent to p53 mutation. Current dogma holds that Mdm2 binding alone is sufficient to block p53's transcriptional activity. In contrast, our in vivo data show that Mdm2 binding does not adequately repress p53, at least not to an extent allowing mouse embryo development. Furthermore, we show that Mdm2 autodegradation is not the principle mechanism for Mdm2 degradation in vivo. Our in vivo evidence calls for a revision to current dogma regarding Mdm2's regulation of both p53 and itself.
with a heterologous Gal4 DNA-binding domain, Mdm2 is capable of repressing basal transcription via a sequence, comprising Mdm2 residues 50-222, that appears to be separate from its p53-binding site (Thut et al., 1997) . Notably, this inhibitory domain overlaps with an Mdm2 domain at residues 102-222 that is required for binding with the transcription cofactor p300/CBP (Grossman et al., 1998) , suggesting that Mdm2 could interfere with p53 transcription through interaction with these cofactors, given that p300/CBP augments p53 transcriptional activity by promoting acetylation of p53 C-terminal lysine residues. Intriguingly, these C-terminal acetylation sites of p53 are also essential for Mdm2-induced ubiquitination and subsequent degradation of p53, thus indicating a potential connection between p53 transcriptional function and Mdm2-induced ubiquitination. However, it has not been shown whether Mdm2-p53 binding alone is sufficient, or whether Mdm2-mediated ubiquitination is also required, for Mdm2 to repress p53.
Mdm2-mediated p53 ubiquitination and degradation have drawn significant attention in recent years. Mdm2 belongs to a large family of RING finger ubiquitin ligases. The RING finger motif is characterized by a group of conserved cysteine and histidine residues that form a crossbrace structure upon binding of two zinc ions. This structure interacts with E2 ubiquitin-conjugating enzymes and facilitates ubiquitination of bound substrates. Mdm2's ligase activity is completely abolished by mutations at any of the eight cysteine and histidine residues involved in zinc coordination, and it can also be inhibited by a metal chelator, indicating a requirement for the correct zincdependent folding of the RING finger. It is now generally accepted that Mdm2 is the principal p53 ubiquitin ligase (Yang et al., 2004) . Mice with targeted deletion of the Mdm2 gene die during early embryonic development, and this lethality can be rescued by concomitant deletion of p53, indicating that the embryonic lethality of Mdm2 null mice is due to activation of p53 (Jones et al., 1995; Luna et al., 1995) .
Functions other than E3 ubiquitin ligase activity have been ascribed to the Mdm2 RING domain. For example, this region of Mdm2 can bind to RNA (Elenbaas et al., 1996) , and it also harbors a cryptic nucleolar localization signal that is exposed under certain circumstances such as p14ARF binding (Lohrum et al., 2000) . Moreover, the Mdm2 RING domain can bind nucleotides such as ATP, an activity important for Mdm2 nucleolar localization (Poyurovsky et al., 2003) . Recently, it was shown that the RING domain of Mdm2 forms a spontaneously assembled supramolecular complex in solution (Poyurovsky et al., 2007) . The Mdm2 RING domain also mediates homodimerization with itself and heterodimerization with MDMX (Jackson and Berberich, 2000; Sharp et al., 1999; Stad et al., 2000; Tanimura et al., 1999) , findings confirmed recently in a paper describing the NMR solution structure of the Mdm2 RING domain dimer (Kostic et al., 2006) .
In this study, we generated and investigated mice bearing a single-residue substitution, C462A, in the RING finger domain of Mdm2. Our mouse model reveals two unexpected insights into the mechanism for Mdm2 RING-mediated E3 ligase activity: (1) the Mdm2-p53 physical interaction alone, without Mdm2-mediated p53 ubiquitination, is unable to suppress p53 activity; and (2) the Mdm2 RING-mediated E3 ubiquitin ligase function is dispensable for Mdm2 degradation.
RESULTS
Mice Homozygous for Mdm2 C462A Mutation Die during Embryonic Development To investigate the in vivo function of the Mdm2 RING finger E3 ubiquitin ligase, we engineered a Cys-to-Ala substitution at the zinc-coordinating residue C462 in the mouse Mdm2 (equivalent to C464 in human HDM2) ( Figure 1A ). This mutation, which alters a structural-crucial zinc coordinating cysteine, has been shown to abolish Mdm2's E3 ubiquitin ligase activity without affecting Mdm2-p53 binding (Geyer et al., 2000) . Correct targeting of the Mdm2 allele by a substitution of TGT > GCC in codon 462, which simultaneously generates an Eag1 restriction site (CGGCCG), was confirmed by Southern blotting ( Figure 1B ) and by Eag1 digestion of PCR-amplified genomic DNA ( Figure 1C ) from the targeted embryonic stem (ES) cells. The targeted allele was reconfirmed by sequencing of the mouse genomic DNA after germline transmission was obtained ( Figure 1D) were empty deciduae or embryos at various stages of reabsorption (Table 2) . These three types of embryos fall into a ratio of approximately 1:2:1, as expected for a heterozygous intercross. We were unable to isolate DNA, without contamination from outside tissues, from the partially reabsorbed embryos. We believe that these reabsorbed embryos are Mdm2 C462A/C462A homozygous. Thus, the
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C462A/C462A embryos must have died prior to E8.5 of gestation.
To establish a more specific timeline for the embryonic lethality, histological analysis of embryos at E6.5-E9.5 was performed. All embryos examined at E6.5 of gestation exhibited visible embryonic architecture ( Figure 1E) , although approximately one-fourth of the embryos appeared somewhat smaller than the others (indicated as ''abnormal''). At E7.5, most embryos exhibited features characteristic of normal development, including gastrulation, initiation of organogenesis, differentiation of the three germ layers (ectoderm, mesoderm, and endoderm), and formation of the three embryonic cavities (ectoplacental, exocoel, and amniotic). In contrast, of the 24 total dissected E7.5 deciduae, 5 (21%) were found to be smaller in size than normal E7.5 embryos and exhibited none of the developmental features of normal E7.5 embryos ( Figure 1E) ; instead, the smaller embryos exhibited a size and structure similar to that of E6.5 embryos (e.g., differentiation of proamniotic cavity and extraembryonic ectoderm). Beyond E7.5, only empty cavities, but not embryos, were evident from the smaller deciduae, most likely resulting from reabsorption of abnormal embryos (data not shown). Of the 93 deciduae examined from 11 female mice at E6.5, E7.5, and E8.5, 27 (29%) exhibited either abnormal or empty embryonic architecture. The abnormal The triangles indicate loxP sites with orientations pointed. Southern blot analysis was used to screen the targeted allele. BamH1 digestion generates a 9.5 Kb fragment from the wild-type allele that can be detected by probes A and B. The targeted allele gives rise to two BamH1 fragments of 4.8 Kb and 6.5 Kb, which can be detected by probes A or B, respectively. The clones containing the C > A mutation on codon 462 were screened by PCR using primers shown by arrows below exon 12 and by digestion of the Eag1 site that was introduced with the mutation. ) happens immediately after implantation, which occurs at E5.5 (Jones et al., 1995; Luna et al., 1995 
C462A Homozygous Embryonic Lethality Can
Be Rescued by Concomitant Deletion of p53
It has been shown previously that the embryonic lethality of Mdm2 À/À mice can be rescued by concomitant deletion of p53, indicating that the lethality in Mdm2 null mice results from unchecked p53 function (Jones et al., 1995; Luna et al., 1995) . We therefore investigated whether the embryonic lethality of Mdm2 C462A/C462A mice was also due to the inability of the mutant Mdm2 to suppress p53. . PCR-based genotyping was performed with genomic DNA isolated from embryos at the indicated gestational days. ;p53 +/À mouse intercrosses. Genomic DNA was isolated from tail biopsies of threeweek-old mice. For Mdm2 genotyping, DNA was PCR amplified with primers shown in Figure 1A and digested with Eag1. For p53 genotyping, the DNA was amplified using primers specific for mutant and wild-type alleles (information from The Jackson Laboratory). m/m, Mdm2 C462A/C462A homozygous locus. less Mdm2 than the wild-type MEFs ( Figure 2C ), due to a lack of the Mdm2-transactivator p53. Cancer Cell from unchecked p53 activity. These data also suggest that the Mdm2-p53 interaction, in the absence of Mdm2-mediated p53 ubiquitination, cannot sufficiently suppress p53's transactivation activity, at least toward the p21 gene.
To ascertain that the in vivo Mdm2 C462A protein is able to interact physically with p53, whole-cell lysates, in the presence of 4-OHT, were isolated and analyzed for Mdm2's interaction with p53ER, and with ribosomal proteins L5 and L11 as controls, by immunoprecipitationcoupled western blotting (IP-western) ( Figure 3B Figure 4C ) were essentially identical to those measured in MEFs without p53 ( Figure 4B ), even though the Mdm2 C462A protein was expressed to a very high level (as shown in Figure 3A ). These data further suggest that high levels of Mdm2 Cancer Cell RING mutant, HDM2 was rapidly degraded in the Mdm2 C462A/C462A ;p53 À/À MEFs. The half-life of the wildtype HDM2 was similar to that of endogenous Mdm2, at about 20 min, whereas the RING mutant HDM2 was resistant to degradation ( Figure 4D ). Thus, the data indicate that the Mdm2 RING E3 function is required for degradation of ectopically overexpressed Mdm2, but not for endogenously expressed Mdm2.
DNA Damage Induces Destabilization of Mdm2 Regardless of Mdm2 RING E3 Function
Previous studies have shown that Mdm2's half-life decreases after cells are treated with DNA-damaging agents (Stommel and Wahl, 2004 ; p53 À/À MEFs with 10 Gy gamma irradiation followed by a protein half-life assay. Consistent with a previous in vitro study, the half-life of wild-type Mdm2 was shortened after cells were exposed to gamma irradiation, from 20 min in untreated cells to approximately 5 min in treated cells ( Figure 5A ). Importantly, the half-life of the Mdm2 ;p53 À/À MEFs were transfected with plasmid DNA expressing HDM2 or HDM2 C464A along with a GFP plasmid. Twenty-four hours after transfection, the cells were treated with cycloheximide (50 mg/ml) and chased for the indicated times. Ectopically expressed HDM2 and HDM2 C464A were detected by HDM2-specific antibody 4B11. GFP was detected by anti-GFP antibody and served as transfection efficiency control. The amount of HDM2 remaining at each time point was quantified by densitometry, normalized relative to the amount of GFP, and plotted to the right.
Consistently, in spite of the presence of active p53ER, which induces expression of Mdm2, both the wild-type and RING mutant Mdm2 were rapidly degraded after gamma irradiation, with a half-life of less than 10 min for each protein. ; p53 À/À MEFs to transactivate endogenous Mdm2 and to achieve comparable high levels of wild-type and mutant Mdm2 protein. We then treated the cells with MG132 and lysed them directly in hot SDS lysis buffer (hot SDS buffer protects Ub-conjugated proteins from deubiquitination during sample preparation). To enrich the total amount of Mdm2 protein so that polyubiquitinated species could be detected, the cell lysates were immunoprecipitated with anti-Mdm2 antibody and resolved on an SDS-PAGE gel followed by western blotting, using antiMdm2 antibody. We estimate that approximately 1.5 3 10 7 cells (from three p100 plates) were used for each IP sample. As shown in Figure 6B , high-molecular-weight ladders/smears, indicative of polyubiquitinated species, were observed in both the wild-type and the RING mutant Mdm2, and the smears were more pronounced after MG132 treatment ( Figure 6B , Long exp), indicating that these smears are polyubiquitinated Mdm2. Importantly, the high-molecular-weight ladders/smears were observed at equal levels for Mdm2 isolated from lysates of both Mdm2 +/+ ;p53 À/À and Mdm2 C462A/C462A ;p53
MEFs. We believe that the high-molecular-weight ladders/smears observed in the Mdm2 C462A mutant are polyubiquitinated Mdm2 C462A protein, because they were identical to those from the wild-type Mdm2 and were enhanced by MG132 treatment. Thus, the RING mutant Mdm2 C462A can be polyubiquitinated in vivo. Finally, to confirm that the in vivo Mdm2 C462A mutant is indeed inactive in promoting p53 polyubiquitination, we transiently expressed p53 in three p53 null MEFs (Mdm2 À/À ;p53
, and Mdm2
C462A/C462A
;p53
) and examined p53 polyubiquitination by a hot SDS-coupled straight western blotting assay. As shown in Figure 6C , a high-molecular-weight ladder of p53-indicative of polyubiquitinated p53 species-was observed only in and Mdm2 C462A/C462A ;p53 À/À MEFs, indicating that the Mdm2 C462A mutant is unable to promote p53 polyubiquitination.
DISCUSSION
Mdm2 is frequently amplified/overexpressed in human tumors, many of which lack mutations in the p53 gene (Leach et al., 1993) , leading to the assumption that Mdm2 overexpression is functionally equivalent to p53 mutation (Momand et al., 1998) . Our initial rationale for generating Mdm2 RING mutant mice was to test whether a high level of Mdm2, due to lack of self-ubiquitination and degradation, might directly bind to and inhibit the activity of p53, causing cancer formation in the absence of p53 mutations; such a model would recapitulate human cancers with Mdm2 amplification. However, knockin of the Mdm2 RING finger mutation in the mouse resulted instead in embryonic lethality and revealed two unexpected insights into the Mdm2-imposed p53 repression: (1) the Mdm2-p53 physical interaction, in the absence of Mdm2-mediated p53 ubiquitination, cannot suppress p53 activity sufficiently to allow mouse early embryonic development; and (2) the Mdm2 RING-mediated E3 ubiquitin ligase function is not required for Mdm2 degradation. Our data raise questions about a widely held view of the mechanism of Mdm2-mediated p53 inhibition, in which it is believed that the binding of Mdm2 with p53's N-terminal transactivation domain interferes with p53's interaction with basal transcriptional machinery, blocking p53's transcriptional activity Thut et al., 1997) . Although we cannot rule out the possibility that the physical interaction between Mdm2 and p53 still inhibits p53 function to a certain extent, or toward a specific set of target genes, our study has otherwise indicated that Mdm2 binding alone, without inducing p53 ubiquitination, is unable to suppress p53 activity in vivo, at least to a degree allowing mouse embryos to develop. Even when expressed at a very high level in the Mdm2 C462A/C462A ;p53 ER/À MEFs upon 4-OHT induction, the mutant Mdm2 C462A , unlike wild-type Mdm2, cannot suppress p53 activity, at least toward p21 and Mdm2 induction ( Figure 3A ). This finding suggests that Mdm2 RING E3 activity is likely the major-if not the only-biochemical activity required to suppress p53, regardless of whether by direct ubiquitination of p53 or by ubiquitination of intermediary proteins (Minsky and Oren, 2004) . The Mdm2-mediated p53 ubiquitination could serve multiple distinct functions, such as tagging p53 for proteasomal degradation, promoting p53 cytoplasmic translocation, and directly suppressing p53 transcriptional activity by, for example, blocking access of transcription cofactors. In this regard, it is tempting to say that the principal mechanism involved in activating p53 upon a variety of cellular stresses could be simply to inhibit Mdm2's E3 ubiquitin ligase activity, thereby releasing p53 from ubiquitination-mediated repression. The notion that blocking Mdm2-induced p53 ubiquitination, without disrupting the Mdm2-p53 interaction, could be sufficient to release p53 activity provides a potential unified mechanism for the action of many Mdm2 inhibitors, such as ARF and L11, whose association with Mdm2 and inhibition of the Mdm2 E3 ubiquitin ligase function would be sufficient to activate p53 without necessarily disrupting the Mdm2-p53 physical interaction. Our data also call into question the role of Mdm2's RING-mediated E3 ubiquitin ligase function in Mdm2 self-degradation. Previous studies using in vitro ectopic (Figures 4 and 5) , and that the Mdm2 C462A mutant protein is sensitive to MG132-induced stabilization (Figure 6 ), predict the existence of other ubiquitin E3s for Mdm2 degradation. Consistent with this notion, a recent study has shown that the histone acetyltransferase PCAF can negatively regulate Mdm2 by promoting Mdm2 ubiquitination and degradation (Linares et al., 2007) . We do not rule out that Mdm2 autoubiquitination may occur when the protein is expressed at extremely high levels, or that the C462A point mutation itself may cause unforeseen effects on protein stability. However, given the stark deviation between the in vitro and in vivo results for Mdm2 autodegradation revealed by the Mdm2 C462A mutant knockin, alternative mechanisms for Mdm2 ubiquitination and degradation, including PCAF-induced degradation, warrant further investigation with an in vivo system. The finding that inhibiting Mdm2-induced p53 ubiquitination, while retaining Mdm2-p53 binding, results in embryonic lethality has intriguing implications. It has been demonstrated that Mdm2 and Mdm4 (a.k.a. Mdmx) interact with each other via their respective RING domains, and that the Mdm2 RING finger mutation disrupts Mdm2-Mdm4 binding (Kawai et al., 2003) . We have not determined whether, under physiological conditions, the Mdm2 C462A mutant protein can interact with Mdm4.
Whether the Mdm2-Mdm4 interaction is essential for activating Mdm2's E3 ubiquitin ligase activity toward p53, and whether Mdm2-mediated p53 ubiquitination plays any role in determining p53's decision between growth arrest and apoptosis, remain interesting questions that can now be addressed with the Mdm2 RING mutant mouse model.
EXPERIMENTAL PROCEDURES
Generation of Mdm2 C462A Mutant Mice
Murine 129/Sv genomic DNA containing the last six exons (7-12) of Mdm2 was a gift from Dr. Lozano (University of Texas, M.D. Anderson Cancer Center). The targeting vector was constructed in a PGK neo vector. A cysteine to alanine substitution was introduced in codon 462 using site-directed mutagenesis, and a new Eag1 restriction site was generated at the same time. The final construct was sequenced using overlapping primers. Electroporation of 129/Sv-derived AB2.2 ES cells was performed by the UNC Animal Models Core Facility. DNA isolated from 192 G418-resistant ES colonies was subjected to BamH1 digestion followed by Southern blotting analysis using a probe covering intron 9 between exons 9 and 10. Positive clones were further confirmed for the presence of the C462A substitution by PCR amplification of genomic DNA using primers flanking exon 12, followed by Eag1 digestion. Two positive clones were injected into C57BL/6 blastocysts, and the blastocysts were transferred into pseudopregnant CD1 female recipients. The resulting chimeric males were mated with C57BL/6 females. Germline transmissions were confirmed by Southern blotting and PCR analysis.
Mouse Breeding, Maintenance, and Genotyping Eleven chimeric mice generated from ES cells were mated with C57BL/6 females. The progeny agouti mice were genotyped by PCR and Eag1 digestion to screen for germline transmission. The germline-transmitted Mdm2 +/C462A heterozygous mice were crossed with EIIa-Cre transgenic mice (The Jackson Laboratory) to delete the neomycin selection marker and were backcrossed to C57BL/6 mice for four generations and maintained on a mixed 129/Sv 3 C57BL/6 background. The mice and embryos were analyzed in comparison to their own littermates. The p53 null mice (p53
) were purchased from The Jackson Laboratory. p53ER TAM knockin mice and genotyping of the p53ER TAM alleles were described previously (Christophorou et al., 2005 CCTTAT-3 0 ) and mutant (p53-X7; NEO18.5, 5 0 -TCCTCGTGCTTTA CGGTATC-3 0 ) p53 alleles were described by The Jackson Laboratory.
Southern Blotting and RT-PCR Analysis
Southern blotting analysis was performed using NEN Life Science GeneScreen kit with a 1 Kb probe that recognizes intron 9 of Mdm2 as indicated in Figure 1A . For RT-PCR, total RNA was extracted using the Total RNA Isolation kit (Promega). The primers were as follows: 
Histological and Histochemical Analysis of Mouse Embryos
Embryos were fixed overnight in 10% formalin (buffered to neutral). The formalin-fixed embryos were paraffin embedded at the Histopathology Core Facility. Sections (5 mm) were cut and stained with hematoxylin and eosin (H&E).
Cell Culture
Primary MEF cells were cultured in a 37 C incubator with 5% CO 2 in DMEM supplied with 10% FBS and penicillin (100 IU/ml)/streptomycin (100 mg/ml). Cells were maintained by 3T3 protocol, and cell number was counted with a hematocytometer. pBabe retrovirus vector encoding murine p53 was a gift from Dr. Peiqing Sun (Scripps, CA), and the temperature-sensitive p53 (tsp53) mutant p53 A135V was made by PCRbased site-directed mutagenesis. p53 null MEFs expressing Mdm2 +/+ and Mdm2 C462A/C462A were infected with retroviruses carrying tsp53 at 37 C, selected with puromycin (2.5 mg/ml) for 3 days at 39.0 C, and maintained at 39.0 C until shifting temperature to 32 C for p53 activation. Procedures for production and infection of retroviruses and adenoviruses were described previously (Itahana et al., 2003) . For activation of p53ER TAM , 100 nM 4-hydroxytamoxifen (Sigma) dissolved in 100% ethanol was added to the culture medium.
Protein Analysis
Mouse monoclonal Mdm2 (2A-10 and 4B11, Calbiochem), p53 (NCL-505, Novocastra; DO-1,Lab Vision/Neomarkers), actin (MAB1501, Chemicon International), goat polyclonal p53 (FL-393; Santa Cruz), and rabbit polyclonal p53 (CM5, Novocastra) antibodies were purchased commercially. Rabbit polyclonal antibodies to p21 were gifts from Dr. Yue Xiong (UNC-Chapel Hill). Rabbit polyclonal antibodies to L5 and L11 were previously described (Lindstrom et al., 2007) . Cells were lysed in 0.1% NP-40 buffer for immunoprecipitation and 0.5% NP-40 buffer for straight western blotting. Procedures and conditions for immunoprecipitation and immunoblotting were described previously (Itahana et al., 2003) . The half-life of Mdm2 protein was measured by treating cells with cycloheximide (50 mg/ml) for indicated length of time. The Mdm2 level was analyzed by western blotting, and the intensity of the bands in the linear range of exposure was quantified by densitometry.
In Vivo Ubiquitination Assay MEF cells were lysed in 1% SDS lysis buffer (1% SDS and 1% NP-40 in PBS). The cell lysates were diluted ten times with 0.1% NP-40-PBS containing 1 mM phenylmethylsulfonyl fluoride (PMSF). The diluted lysates were precleared with Sepharose CL4B beads (Sigma) for 30 min and then immunoprecipitated with anti-Mdm2 antibody (2A10) overnight at 4 C, followed by incubation with protein A beads (Pierce) for 2 hr at 4 C. The beads were washed four times with cold 0.1% NP-40-PBS containing 1 mM PMSF. The beads were then incubated in 13 SDS loading buffer.
